Collard J, Dufrasne M
Sem Hop. 1978;54(29-32):958-60.
In order to determine the psychopharmacological profile of tiapride, the authors carried out 3 studies. The first study of ten resistant psychiatric cases permitted us to detect the direction of later studies. The object of the second was to analyse the neurovisceral properties and the action of tiapride on somatic symptoms due to anxiety in 25 ambulatory patients. The last study was a therapeutic approach. Tiapride appears to be one of the best drugs for anxiety in one of the 3 following circumstances: a paroxysmal or chronic somatic expression, depression, or behaviour suggesting latent and masked psychosis or early psychosis. Tiapride is tolerated in the same way as a neuroleptic for even in low dosage (150-300 mg/day) may appear undesirable side effects of extrapyramidal type. On the other hand, and contrary to sulpiride, neuro-endocrine effects are exceptional.
为了确定硫必利的精神药理学特征，作者开展了3项研究。第一项研究针对10例难治性精神病病例，使我们能够确定后续研究的方向。第二项研究的目的是分析25例门诊患者的神经内脏特性以及硫必利对焦虑所致躯体症状的作用。最后一项研究是一种治疗方法。硫必利似乎是以下3种情况中治疗焦虑症的最佳药物之一：阵发性或慢性躯体表现、抑郁，或提示潜在和隐匿性精神病或早期精神病的行为。硫必利的耐受性与抗精神病药物相同，因为即使在低剂量（150 - 300毫克/天）时也可能出现锥体外系类型的不良副作用。另一方面，与舒必利相反，神经内分泌作用罕见。
